| 1‐Methylnicotinamide (MNA), a primary metabolite of nicotinamide, exerts anti‐thrombotic activity mediated by a cyclooxygenase‐2/prostacyclin pathway S Chlopicki, J Swies, A Mogielnicki, W Buczko, M Bartus, M Lomnicka, ... British journal of pharmacology 152 (2), 230-239, 2007 | 231 | 2007 |
| The toxicology of heparin reversal with protamine: past, present and future E Sokolowska, B Kalaska, J Miklosz, A Mogielnicki Expert opinion on drug metabolism & toxicology 12 (8), 897-909, 2016 | 138 | 2016 |
| The physiological significance of the alternative K Kramkowski, A Mogielnicki, W Buczko J. Physiol. Pharmacol 57, 529-539, 2006 | 138 | 2006 |
| L-arginine and cardiovascular system D Cylwik, A Mogielnicki, W Buczko Pharmacol Rep 57 (1), 14-22, 2005 | 119 | 2005 |
| Angiotensin II enhances thrombosis development in renovascular hypertensive rats A Mogielnicki, E Chabielska, R Pawlak, J Szemraj, W Buczko Thrombosis and haemostasis 93 (06), 1069-1076, 2005 | 89 | 2005 |
| ANGIOTENSIN II VIA AT1 RECEPTOR ACCELERATES ARTERIAL M Kamińska, A Mogielnicki, A Stankiewicz, K Kramkowski, ... Journal of Physiology and Pharmacology 56 (4), 571-585, 2005 | 76 | 2005 |
| Antithrombotic properties of water-soluble carbon monoxide-releasing molecules K Kramkowski, A Leszczynska, A Mogielnicki, S Chlopicki, A Fedorowicz, ... Arteriosclerosis, thrombosis, and vascular biology 32 (9), 2149-2157, 2012 | 64 | 2012 |
| IN FOCUS: A new recombinant thrombolytic and antithrombotic agent with higher fibrin affinity–a staphylokinase variant. I. In vitro study J Szemraj, B Walkowiak, I Kawecka, G Janiszewska, W Buczko, ... Journal of Thrombosis and Haemostasis 3 (10), 2156-2165, 2005 | 61 | 2005 |
| Inhibition of platelet aggregation by carbon monoxide-releasing molecules (CO-RMs): comparison with NO donors S Chlopicki, M Lomnicka, A Fedorowicz, E Grochal, K Kramkowski, ... Naunyn-schmiedeberg's Archives of Pharmacology 385, 641-650, 2012 | 57 | 2012 |
| Antithrombotic effects of pyridinium compounds formed from trigonelline upon coffee roasting B Kalaska, L Piotrowski, A Leszczynska, B Michalowski, K Kramkowski, ... Journal of agricultural and food chemistry 62 (13), 2853-2860, 2014 | 47 | 2014 |
| Angiotensin-(1-9), the product of angiotensin I conversion in platelets, enhances arterial thrombosis in rats K Kramkowski, A Mogielnicki, A Leszczynska, W Buczko Journal of Physiology and Pharmacology 61 (3), 317, 2010 | 47 | 2010 |
| Angiotensin-(1–9) enhances stasis-induced venous thrombosis in the rat because of the impairment of fibrinolysis A Mogielnicki, K Kramkowski, JM Hermanowicz, A Leszczynska, ... Journal of the Renin-Angiotensin-Aldosterone System 15 (1), 13-21, 2014 | 39 | 2014 |
| Cationic derivative of dextran reverses anticoagulant activity of unfractionated heparin in animal models of arterial and venous thrombosis B Kalaska, E Sokolowska, K Kaminski, K Szczubialka, K Kramkowski, ... European journal of pharmacology 686 (1-3), 81-89, 2012 | 39 | 2012 |
| ANTITHROMBOTIC EFFECT OF TISSUE AND PLASMA TYPE M Wojewódzka-Elezniakowicz, E Chabielska, A Mogielnicki, ... Journal of physiology and pharmacology 57 (2), 231-245, 2006 | 39 | 2006 |
| N-methylnicotinamide inhibits arterial A Mogielnicki, K Kramkowski, L Pietrzak, W Buczko Journal of Physiology and Pharmacology 58 (3), 515-527, 2007 | 38 | 2007 |
| Nonclinical evaluation of novel cationically modified polysaccharide antidotes for unfractionated heparin B Kalaska, K Kaminski, E Sokolowska, D Czaplicki, M Kujdowicz, ... PLoS One 10 (3), e0119486, 2015 | 36 | 2015 |
| Aspirin and the fibrinolytic response W Buczko, A Mogielnicki, K Kramkowski, E Chabielska Thrombosis research 110 (5-6), 331-334, 2003 | 32 | 2003 |
| Heparin-binding copolymer reverses effects of unfractionated heparin, enoxaparin, and fondaparinux in rats and mice B Kalaska, K Kaminski, J Miklosz, S Yusa, E Sokolowska, A Blazejczyk, ... Translational Research 177, 98-112. e10, 2016 | 30 | 2016 |
| Antithrombotic effect of L-arginine in hypertensive rats D Cylwik, A Mogielnicki, K Kramkowski, J Stokowski, W Buczko Journal of physiology and pharmacology 55 (3), 563-574, 2004 | 29 | 2004 |
| The toxicokinetic profile of Dex40-GTMAC3—a novel polysaccharide candidate for reversal of unfractionated heparin E Sokolowska, B Kalaska, K Kaminski, A Lewandowska, A Blazejczyk, ... Frontiers in Pharmacology 7, 60, 2016 | 23 | 2016 |
